Current and Future Treatments for Alzheimer's Disease

CNS Spectrums

Volumn 14, Issue S7, 2009, Pages 4-7

  Salloway, Stephen ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; DRUG THERAPY; FORECASTING; HISTORY; HUMAN; PARASITOLOGY; REVIEW;

ALZHEIMER DISEASE; DRUG THERAPY; FORECASTING; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS;

EID: 73349132713     PISSN: 10928529     EISSN: 21656509     Source Type: Journal    
DOI: 10.1017/S1092852900024895     Document Type: Article

References (29)

1. Alzheimer's Association. Alzheimer's Disease Facts and Figures. Available at: www.alz.org/alzheimers_disease_facts_figures.asp. Accessed July 2,2009.
2. Brookmeyer, R, Johnson, E, Ziegler-Grahamm, K, Arrighi, M. Forecasting the global prevalence and burden of Alzheimer's disease. Alzheimers Dement. 2007; 3: S168–S169.
3. US Census Bureau News. Census Bureau Reports World's Older Population Projected to Triple by 2050. Washington. DC: US Census Bureau News; 2009. Available at: www.census.gov/Press-Reiease/www/releases/archives/international_population/013882.html. Accessed July 2, 2009.
4. Evans, DA, Funkenstein, HH, Albert, MS, et al. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA. 1989: 262(18):2551–2556.
5. von Strauss, E, Viitanen, M, De Ronchi, D, Winblad, B, Fratiglioni, L. Aging and the occurrence of dementia: findings from a population-based cohort with a large sample of nonagenarians. Arch Neurol. 1999; 56(5):587–592.
6. Sofi, F, Cesari, F, Abbate, R, Gensini, GF, Casini, A. Adherence to Mediterranean diet and health status: meta-analysis. BMJ. 2008; 337: a1344.
7. Stauffer, B. Alzheimer's Century: On the 100th anniversary of Dr. Alzheimer's discovery, new scientific advances fight a scourge of the 21st century. Neurology Now. 2006; 2(2):34.
8. Rossor, MN, Iversen, LL, Reynolds, GP, Mountjoy, CO, Roth, M. Neurochemical characteristics of early and late onset types of Alzheimer's disease. BrMedJIClin Res Ed). 1984; 288(6422):961–964.
9. Goedert, M, Spillantini, MG. A century of Alzheimer's disease. Science. 2006; 314(5800):777–781.
10. Hansson, O, Zetterberg, H, Buchhave, P, Londos, E, Blennow, K, Minthon, L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006; 5(3):228–2234.
11. Klunk, WE, Engler, H, Nordberg, A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004; 55(3):306–319.
12. Dubois, B, Feldman, HH, Jacova, C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007; 6(8):734–746.
13. Allain, H, Schück, S, Lebreton, S, et al. Aminotransferase levels and silymarin in de novo tacrine-treated patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 1999; 10(3):181–185.
14. Tariot, PN, Farlow, MR, Grossberg, GT, Graham, SM, McDonald, S, Gergel, I, and the Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004; 291(3):317–324.
15. Courtney, C, Farrell, D, Gray, R. et al, and the AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet. 2004; 363(9427):2105–2115.
16. Fillit, HM, Doody, RS, Binaso, K, et al. Recommendations for best practices in the treatment of Alzheimer's disease in managed care. Am J Geriatr Pharmacother. 2006; 4(suppl A):S9–S24.
17. Finehout, EJ, Franck, Z, Choe, LH, Relkin, N, Lee, KH. Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease. Ann Neurol. 2007: 61(2):120–129.
18. Aisen, PS. Gauthier, S, Vellas, B, et al. Alzhemed: a potential treatment for Alzheimer's disease. Curr Alzheimer Res. 2007; 4(4):473–478.
19. Xaliproden: SR 57746, SR 57746A. xaliproden hydrochloride, xaliprodene. Drugs R D. 2003: 4(6):386–388.
20. Woodman, R. Sanofi's Alzheimer's drug xaliproden fails in Phase 3. APM Health Europe. September 17, 2007. Available at: http://www.apmhealtheurope.com/story.php?mots=UPDATE&searchScope=1&searchType=0&numero=L8198. Accessed July 2. 2009.
21. Williams, M. Progress in Alzheimer's disease drug discovery: an update. Curr Opin Investig Drugs. 2009; 10(1):23–34.
22. Jones, RW, Kivipelto, M, Feldman, H, et al, and the LEADe investigators. The Aton/astatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics. Alzheimers Dement. 2008; 4(2):145–153.
23. Burton, A. 9th International Conference on AD and related disorders (ICAD). Lancet Neurol. 2004; 3(9):510.
24. Marder, K. Vaccine trial in Alzheimer's disease is halted. Curr Neurol Neurosci Rep. 2003: 3(5):371–372.
25. Holmes, C., Boche, D, Wilkinson, D, et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008: 372(9634):216–223.
26. Brown, ME, DaSilva, KA, McLaurin, J. Refining an Alzheimer's vaccine to avoid an inflammatory response. Expert Opin Biol Ther. 2005; 5(6):809–816.
27. ClinicalTrials.gov Identifier NCT00568776. ELND005 in Patients With Mild to Moderate Alzheimer's Disease. Available at: clinicaltrials.gov/ct2/show/NCT00568776. Accessed July 2, 2009.
28. Salloway, S. Mintzer, J. Weiner, MF, Cummings, JL. Disease-modifying therapies in Alzheimer's disease. Alzheimers Dement. 2008; 4(2):65–79.
29. Doody, RS, Gavrilova, SI, Sano, M, et al, and the dimebon investigators. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet. 2008; 372(9634):207–215.